KU Leuven Spin-Off Possibly Has New Way to Attack Autoimmune Disease

KU Leuven Spin-Off Possibly Has New Way to Attack Autoimmune Disease

Why would a new immunotherapy approach be cause for researchers to reconsider Type 1 diabetes and its treatment?  Perhaps a novel modified synthetic peptide-based technology platform known as Imotopes™ could pave the path for new classes of therapies that block improper autoimmune responses. This new approach comes from the team at Imcyse, SA, a small biotech operating in the Walloon Region of Belgiumm which is actually originally a spin-off from Belgium’s KU Leuven. Known as Imcyse, they have raised over $40 million and now gear up for an important Phase 1/2 clinical trial in Belgium and the UK.

The Challenge Addressed

As recently shared in Open Access Government, growing autoimmune diseases, especially the severe and chronic type, represent extremely difficult and complex immune-system-based indications. It's not a secret that autoimmune disease continues to rise. Although there are no readily available macro-answers, scientists do know that in these situations where the immune system goes haywire, that is, it mistakenly focuses on healthy cells as external invaders, attacking them in the process. Hence the patient’s immune system essentially seeks to destroy the host’s ow...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee